---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-229043"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2022-08-25T23:59:59+00:00"
generated_at: "2026-06-23T21:21:39.238371+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CEO Quinn departs; interim CEO Kastenmayer named; restructuring cuts headcount 25%, prioritizes AGLE-177

## Summary
- CEO Anthony Quinn departed Aug 24, 2022 via mutual agreement; no disagreement; to serve as R&D Advisor then consultant through Sept 2023.
- James Kastenmayer (General Counsel) appointed Interim CEO; base salary raised to $588,000, target bonus set at 50%.
- Michael Hanley promoted to Chief Business Officer from Chief Commercial Officer.
- Restructuring reduces headcount ~25% YTD; transitions patients out of pegzilarginase extension studies in Arginase 1 Deficiency.
- Company prioritizes AGLE-177 development; expects cash runway extended into Q4 2023.

## SEC filing metadata
- accession: 0001193125-22-229043
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2022-08-25T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312522229043/0001193125-22-229043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312522229043/d253845d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-229043
- JSON: https://secwatch.observer/filing/0001193125-22-229043.json
- Plain text: https://secwatch.observer/filing/0001193125-22-229043.txt

## Key facts
- Executive change
  Anthony Quinn changed role as President and Chief Executive Officer at Spyre Therapeutics, Inc..
  - Action: ceased his role as
  - Role: President and Chief Executive Officer
  source text: Dr. Quinn ceased his role as the Company’s President and Chief Executive Officer, effective August 24, 2022 (the “CEO Transition Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312522229043/0001193125-22-229043-index.htm
- Executive change
  James Kastenmayer was appointed as Interim Chief Executive Officer at Spyre Therapeutics, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: Effective as of the Transition Date, the Board appointed James Kastenmayer, the Company’s General Counsel and Corporate Secretary, to succeed Dr. Quinn as Interim Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312522229043/0001193125-22-229043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.